Abstract:Objective: To examine the early outcome of valve sparing aortic root replacement with reimplantation technique (David procedure) with partial upper sternotomy. Methods: From April 2016 to April 2020, 31 patients underwent valve sparing aortic root replacement under partial upper sternotomy at Vascular Surgery Center, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. There were 28 males and 3 females, aging (44±13) years (range: 11 to 65 years). Preoperative aortic regurgitation was found greater than moderate in 15 patients, moderate in 6 patients and less than moderate in 10 patients. The diameter of aortic annulus was (26±3) mm (range: 21 to 34 mm), the diameter of aortic sinus was (51±6) mm (range: 41 to 68 mm), the diameter of ascending aorta was (43±8) mm (range: 26 to 62 mm). The preoperative ejection fraction was (65±4) % (range: 59% to 72%) and left ventricular end-diastolic diameter was (55±6) mm (range: 42 to 68 mm). All cases were treated with David Ⅰ procedure, including simple David procedure in 26 patients, David+ascending aorta and partial aortic arch replacement in 3 patients, David+thoracic endovascular aortic repair in 1 patient, David+stent elephant trunk implantation in 1 patient. Results: The operation time, cardiopulmonary bypass time and aortic cross-clamping time were (330±58) minutes (range: 214 to 481 minutes), (138±23) minutes (range: 106 to 192 minutes) and (108±17) minutes (range: 82 to 154 minutes), respectively. There were no death and serious complications (stroke, myocardial infarction, renal insufficiency, severe infection, etc.). The postoperative drainage volume within 24 hours was (314±145) ml (range: 130 to 830 ml). The intubation time was (14±3) hours (range: 8 to 21 hours), and the ICU time was (M(QR)) 2.1(1.5) days (range: 1.0 to 5.0 days). Eight patients had no blood transfusion, the proportion of red blood cell use was 9.7% (3/31), plasma use was 22.6% (7/31), and platelet use was 71.0% (22/31). The postoperative left ventricular ejection fraction was (62±4)% (range: 54% to 69%), and left ventricular end-diastolic diameter was (48±4) mm (range: 39 to 56 mm). After operation, aortic regurgitation was significantly improved, with no more than moderate regurgitation, small to moderate regurgitation in 3 patients, minor regurgitation in 3 patients, micro regurgitation in 12 patients and no regurgitation in 13 patients. The follow-up period was 3.5(6.1) months (range: 2.0 to 39.0 months). Echocardiographic follow-up data were obtained in 26 cases, including moderate regurgitation in 1 patient, small to moderate regurgitation in 9 patients, minor regurgitation in 5 patients, micro regurgitation in 6 patients and no regurgitation in 5 patients. There were no major adverse cardiovascular events and aortic events during the follow-up period. No patient was reoperated for aortic regurgitation. Conclusion: Valve sparing aortic root replacement under partial upper sternotomy is safe and feasible, and the early result is satisfactory.

Balloon-dilated endovascular replacement of aortic valve for severe aortic stenosis:preliminary experience in five cases

Aortic Valve Replacement Via Transfemoral Balloon Dilation: an Initial Experience

Evaluation of the Safety and Efficacy of Transcatheter Aortic Valve Implantation in Patients with a Severe Stenotic Bicuspid Aortic Valve in a Chinese Population.

Operative Nursing Cooperation in Aortic Valve Replacement via Transfemoral Balloon Dilation for Patients with Aortic Valve Stenosis

The Valve Replacement on the Senile Degenerative Heart Valve Diseases

Clinical efficacy of transcatheter aortic valve replacement in treatment of patients with aortic valve stenosis based in a single Chinese center

Transcatheter Aortic Valve Implantation with Balloon-Expandable Valve: Early Experience from China.

Transcatheter aortic valve replacement in atypical valve anatomy using the Lotus valve

Severe Symptomatic Bicuspid and Tricuspid Aortic Stenosis in China: Characteristics and Outcomes of Transcatheter Aortic Valve Replacement with the Venus-A Valve (vol 2, pg 60, 2018)

Clinical Application of Percutaneous Balloon Aortic Valvuloplasty in Patients With Calcified Severe Aortic Stenosis Combining Heart Failure

Chinese domestic transcatheter valve system in the treatment of severe aortic stenosis: analysis of long-term outcomes and predictors

Transcatheter Aortic Valve Implantation: Preliminary Experience in West China Hospital

Feasibility and technicality of aortic valve lithotripsy-facilitate balloon valvuloplasty in patients with severe aortic stenosis unsuitable for immediate valvular replacement

Safety and Efficacy of Transcatheter Aortic Valve Replacement Through Transcarotid Approach for Patients with Severe Aortic Valve Stenosis

[Minimally Invasive Aortic Valve Replacement for Isolated Aortic Valve Disease: Clinical Analysis of 101 Consecutive Patients].

[Preliminary Clinical Experience of the Novel Transcatheter Aortic Valve System Prizvalve® for the Treatment of Severe Aortic Stenosis].

A case report of extracorporeal membrane oxygenation assisted transcatheter aortic valve replacement in a patient with severe aortic valve stenosis and advanced heart failure

A Novel Approach: Trans-Ascending Aorta Balloon Aortic Valvuloplasty Via Sternotomy for Treating Severe Valvular Aortic Stenosis in A Low-Weight Infant

Treatment Congenital Aortic Prolapse by Aortic Valvuloplasty

[Early outcome of valve sparing aortic root replacement with partial upper sternotomy]

Aortic Valve Bypass for High-Risk Patients with Symptomatic Aortic Stenosis: a Case Report